Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan's Nebivolol NDA User Fee Date Extended To May 31

Feb 25 2005

• By Sue Sutter

Related Content

Bertek Submits NDA For Nebivolol; Beta Blocker Would Be Firm’s Third Branded Antihypertensive

May 05 2004

King Inventory Work-Down Plan Goal Is 1.5 Months Of On-Hand Product

Feb 22 2005

Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol

Jul 26 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window